Page 98 of 448: studies 971 to 980 of 4,475, newest first. Back to the ketamine overview
February 27, 2025 Kristin Raj
Ketamine and esketamine show promise in bipolar depression, with 40% of patients responding to twice-weekly treatment. Full remission occurs in 13%. No immediate manic switches occurred during intensive treatment, but 30% experienced hypomania/mania during maintenance phase. Most episodes were mild. Consider involving family members in monitoring mood changes. Patients with severe mania or...
Military Medicine February 27, 2025 Eugene Lipov, Hunter Rolain, Troy Neufeld 1 citation
Canadian Special Operation Forces Command (CANSOFCOM) operators have been extensively deployed in recent conflicts. They are at risk of trauma and blast exposure as well as the development of post-traumatic stress disorder (PTSD) and blast traumatic brain injury (bTBI). Current psychotherapy and pharmacological approaches provide suboptimal resolution of PTSD and bTBI symptoms. Prior research...
Journal of Psychopharmacology February 26, 2025 Sara de la Salle, Jennifer L Phillips, Pierre Blier et al. 3 citations
A sub-anesthetic dose of ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, produces robust antidepressant effects in treatment-resistant major depressive disorder (MDD). The mismatch negativity (MMN) is reliant on glutamatergic neurotransmission and reduced by NMDAR antagonists. The MMN may characterise the neural mechanisms underlying ketamine's effects. This study examined the...
medRxiv Preprint Server February 25, 2025 J Cohen, AC Reichelt, R Zamyadi et al. 1 citation preprint
This detailed case report explores the application of ketamine-assisted psychotherapy (KAP) in the treatment of a male patient in their late 30’s with Generalized Anxiety Disorder (GAD) and depressive symptoms. The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine represents a significant breakthrough in the treatment of mood and anxiety disorders due to its rapid and robust...
Molecular Neurobiology February 24, 2025 Zhe Du, Xiu-Mei Zhu, Peng Lv et al. 2 citations
Psychotic disorder is a significant consequence of ketamine abuse. However, the molecular mechanisms and biomarkers for this psychotic disorder and associated long-term cognitive impairment remain unclear. To investigate the behavioral changes and comprehensive gene expression alterations in mice following ketamine administration, we employed behavioral testing and RNA sequencing (RNA-seq). We...
Naunyn-Schmiedeberg's Archives of Pharmacology February 20, 2025 Atefeh Motamedi-Manesh, Mahdieh Farzin Asanjan, Hamed Fallah et al. 6 citations
Schizophrenia is a severe neuropsychiatric disorder ranking among the top ten global disability causes. In rodents, sub-chronic or chronic ketamine treatment is used for the induction of schizophrenia. Ketamine affects the function of brain-derived neurotrophic factor (BDNF), the most important neurotrophin involved in the pathophysiology of different neuropsychiatric disorders. The present...
Psychiatric Quarterly February 18, 2025 Zhijian Ma, Fengle Wu, Wen Zheng 4 citations
This meta-analysis aimed to compare the efficacy and safety of ketamine versus electroconvulsive therapy (ECT) in patients with major depressive disorder(MDD). A comprehensive literature search was conducted across PubMed, Embase, and Web of Science databases up to November 2024. The randomized controlled trials evaluating the efficacy and safety of ketamine and ECT in MDD patients were...
Journal of Education, Health and Sport February 17, 2025 Urszula Kaczmarska, Michał Jakub Cioch, Julia Nowak et al.
Introduction Depression is one of the most common mental illnesses. Over the course of a lifetime, several percent of the adult population suffers from depression. There are many treatments for depression like pharmacotherapy and psychotherapy. In this article, we wanted to focus on the effectiveness of ketamine in treating depression. Aim of study The study aimed to summarize the available...
Journal of Affective Disorders February 15, 2025 Zhan-Ming Shi, Xian-Jun Lan, Qing Chen et al. 6 citations
Intravenous (IV) ketamine has been evaluated alongside electroconvulsive therapy (ECT) in addressing major depressive disorder (MDD) or bipolar depression (BD), though the comparative outcomes remain inconclusive. This meta-analysis aimed to provide a systematic assessment of the efficacy, safety, and tolerability of IV ketamine relative to ECT for treating MDD or BD. Randomized controlled...
Anesthesia & Analgesia February 13, 2025 Vincent Bonhomme
peer reviewed